Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Medical oncology

Zoledronic acid prevents bone loss in early-stage breast cancer

Nature Reviews Clinical Oncology volume 6, pages 191–192 (2009)Cite this article

Zoledronic acid is effective in the prevention of bone loss in premenopausal women with breast cancer being treated with endocrine therapy. The benefit of zoledronic acid probably extends for some years after cessation of therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Gnant, M. et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 9, 840–849 (2008).

    Article  CAS  Google Scholar 

  2. Saad, F. et al. Cancer treatment-induced bone loss in breast and prostate cancer. J. Clin. Oncol. 26, 5465–5476 (2008).

    Article  Google Scholar 

  3. Ding, H. & Field, T. S. Bone health in postmenopausal women with early breast cancer: how protective is tamoxifen? Cancer Treat. Rev. 33, 506–513 (2007).

    Article  CAS  Google Scholar 

  4. Greenspan, S. L. et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 137, 875–883 (2002).

    Article  CAS  Google Scholar 

  5. Seeman, E. Bone quality: the material and structural basis of bone strength. J. Bone Miner. Metab. 26, 1–8 (2008).

    Article  Google Scholar 

  6. Brufsky, A. et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 13, 503–514 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Verona, Italy

    Francesco Bertoldo

  2. University Campus Bio-Medico, Rome, Italy

    Giuseppe Tonini, Bruno Vincenzi & Daniele Santini

Authors
  1. Francesco Bertoldo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giuseppe Tonini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bruno Vincenzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniele Santini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniele Santini.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bertoldo, F., Tonini, G., Vincenzi, B. et al. Zoledronic acid prevents bone loss in early-stage breast cancer. Nat Rev Clin Oncol 6, 191–192 (2009). https://doi.org/10.1038/nrclinonc.2009.24

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2009.24

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing